Methods of suppressing microglial activation and systemic inflammatory responses
Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. ApoE receptor binding peptides that may be used in the methods of the invention are also described, as are methods of using such peptides to treat peripheral inflammatory conditions such as sepsis. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.
1. A method of treating or reducing the inflammation associated with sepsis in a subject in need thereof, comprising administering to the subject a composition comprising an ApoE peptide, wherein said ApoE peptide is a peptide of 18 to 50 amino acids comprising the sequence of SEQ ID NO: 10, and wherein said composition is administered in an amount sufficient to reduce serum levels of inflammatory cytokines in the subject as compared to that which would occur in the absence of said composition.
2. The method of claim 1 , wherein said inflammatory cytokines include TNFα or IL-6.
3. The method of claim 1 , wherein said composition is administered concurrently or sequentially with one or more anti-inflammatory cytokines or monoclonal antibodies.
4. The method of claim 3 , wherein said anti-inflammatory cytokines are selected from the group consisting of IL-10, transforming growth factor-beta, granulocyte colony-stimulating factor, IFN-phi, macrophage migration inhibitory factor and high mobility group 1 protein.
5. The method of claim 3 , wherein said monoclonal antibodies are selected from the group consisting of antiendotoxin antibodies, anti-tumor necrosis factor antibodies, and anti-CD14 antibodies.
6. A method of treating or reducing the inflammation associated with sepsis in a subject, comprising administering a composition comprising an ApoE peptide, wherein said ApoE peptide consists of the sequence of SEQ ID NO: 10, and wherein said composition is administered in an amount sufficient to reduce serum levels of inflammatory cytokines in the subject as compared to that which would occur in the absence of the composition.